FMP
SCYNEXIS, Inc.
SCYX
NASDAQ
SCYNEXIS, Inc., a biotechnology company, develops products for the treatment fungal infections in the United States. It offers BREXAFEMME (ibrexafungerp tablets) for the treatment of vulvovaginal candidiasis (VVC). The company is developing its lead product candidate, Ibrexafungerp, as a novel oral and intravenous drug for the treatment of various fungal infections, including recurrent VVC, invasive aspergillosis, invasive candidiasis, and refractory invasive fungal infections; and ibrexafungerp that has completed Phase 3 CANDLE study for the prevention of recurrent (VVC). It has research collaborations with Merck Sharp & Dohme Corp., Hansoh (Shanghai) Health Technology Co., Ltd., Jiangsu Hansoh Pharmaceutical Group Company Limited, and R-Pharm, CJSC to develop and commercialize rights for ibrexafungerp. The company was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. SCYNEXIS, Inc. was incorporated in 1999 and is headquartered in Jersey City, New Jersey.
1.12 USD
-0.02 (-1.79%)
InvestorPlace
Jul 22, 2024
Investing in small-cap stocks can be a gateway to high returns, mainly when these companies exhibit strong growth fundamentals and strategic market positioning. Here, the focus is on three stocks to buy under $10.
InvestorPlace
Jul 1, 2024
Every investment category must answer the big question, why? For undervalued biotech stocks, it comes down to advantaging a supremely relevant sector without paying full price.
InvestorPlace
May 31, 2024
The ability to recognize possibilities while investing can frequently be the difference between stagnation and growth in an unstable and changing economic environment. Here are three exciting stocks in technology, insurance, and medicines.
InvestorPlace
May 23, 2024
Finding good prospects is like hunting gold in the fast-paced world of investing. Three stocks stand out in this hunt, all under $10, with significant growth potential.
GlobeNewsWire
Apr 9, 2024
JERSEY CITY, N.J., April 09, 2024 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced the presentation of preclinical efficacy data on its second-generation fungerp candidate SCY-247 at the 34th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) in Barcelona, Spain from April 27-30, 2024.
GlobeNewsWire
Jan 5, 2024
JERSEY CITY, N.J., Jan. 05, 2024 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced the presentation of preclinical efficacy data on its second generation fungerp candidate SCY-247 for the treatment of mucormycosis at the 11th Advances Against Aspergillosis and Mucormycosis (AAAM) Conference in Milan, Italy from January 25 – 27, 2024.
Seeking Alpha
Dec 18, 2023
Scynexis is developing a novel antifungal category called "fungerps" to address antifungal resistance. The company's approved product, ibrexafungerp, has been licensed to GSK with anticipated peak sales of over $500M. Ibrexafungerp commercialization and clinical development was paused due to manufacturing concerns, resulting in a 50% dip in SCYX valuation. However, the issue is expected to be resolved within few months. Considering cash runway >2 years, SCYX is sufficiently funded to resolve the...
Seeking Alpha
Sep 26, 2023
We downgrade Scynexis to a sell rating following the voluntary recall of antifungal pill, Brexafemme. Historical precedence suggests that manufacturing recalls can take months to resolve, and for a single-product biotech, we see further downside to the stock price. Concerns around the impact on clinical trials, partnership with GSK, and uncertainty surrounding hospital-based fungal infection trials remain a key focus/risk moving forward.
Zacks Investment Research
Sep 4, 2023
SCYNEXIS' (SCYX) shares soar 134% year to date, owing to partnership with big wig GSK plc for the development of its antifungal tablet, Brexafemme.
InvestorPlace
Aug 28, 2023
As a rule of thumb, you should stay away from penny stocks. When you see shares priced near a buck (or even below), there's usually a reason for it – and not a good one.